Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews
Authors:
Open Access
- 8 November 2023
- journal article
- review article
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (8) , 2681-2697
Abstract
The present study is an overview of systematic reviews focusing on adverse events of antimyeloma treatments. It provides a systematic description of adverse events as they are reported in the systematic reviews as well as a critical appraisal of included reviews. We conducted a comprehensive literature search in the most widely used electronic databases looking for systematic reviews that had an adverse event of an antimyeloma treatment intervention as primary outcome. Two independent reviewers conducted selection of included studies and data extraction on predesigned online forms and assessed study quality using AMSTAR 2. Overall corrected covered area (CCA) was calculated to examine the overlap of primary studies across systematic reviews. After screening eligible studies, 23 systematic reviews were included in this overview. Seven reviews with overall CCA of 14.7% examined cardiovascular adverse events of different drugs, including immunomodulatory drugs and proteasome inhibitors (mainly carfilzomib). Nine focused on infections, presenting with overall CCA of 5.8%, each one focused on a different drug or drug class. Three studied thromboembolism in patients treated either with lenalidomide, any immunomodulatory drug, or with daratumumab and had an overall CCA equal to 1.5%. Four more reviews focused on bortezomib-associated neurotoxicity, carfilzomib-associated renal toxicity, or second primary malignancies as an adverse event of lenalidomide or anti-CD38 monoclonal antibody treatment. The quality of included studies as judged by AMSTAR 2 was mostly critically low. Absence of a priori registered protocol and formal assessment of risk of bias of included primary studies were the most common shortcomings. Reporting of antimyeloma drug-associated toxicity is supported by multiple systematic reviews; nevertheless, methodological quality of existing reviews is mostly low.Keywords
Funding Information
- Aristotle University of Thessaloniki
This publication has 67 references indexed in Scilit:
- Systematic review finds overlapping reviews were not mentioned in every other overviewJournal of Clinical Epidemiology, 2014
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataThe Lancet Oncology, 2014
- Thalidomide thromboprophylaxis in multiple myeloma: A review of current evidenceAsia-Pacific Journal of Clinical Oncology, 2012
- Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2011
- Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendationsHaematologica, 2010
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guidelineBritish Journal of Haematology, 2009
- Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literatureBlood, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia, 2007
- Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With BortezomibJournal of Clinical Oncology, 2006